EGFR and neoplasm: The administration of EGFR‐TKI itself has been reported to change the tumor immune microenvironment (TIME), including reduced PD‐L1 expression and forkhead box P3 (Foxp3)‐positive T cell reduction,26, 27, 28, 29 and this change in PD‐L1 expression has been cited as a reason for the poor effectiveness of ICI after the acquirement of EGFR‐TKI resistance.27, 30